2. Academic Validation
  3. Clinical review on triglycerides

Clinical review on triglycerides

  • Eur Heart J. 2020 Jan 1;41(1):99-109c. doi: 10.1093/eurheartj/ehz785.
Ulrich Laufs 1,  Klaus G Parhofer 2,  Henry N Ginsberg 3,  Robert A Hegele 4
Affiliations

Affiliations

  • 1 Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, Leipzig, Germany.
  • 2 University Munich, Medical Department 4 - Grosshadern, Marchioninistr. 15, Munich, Germany.
  • 3 Irving Institute for Clinical and Translational Medicine, Vagelos College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY, USA.
  • 4 Department of Medicine, Robarts Research Institute, Western University, London, Ontario, Canada.
PMID: 31764986 DOI: 10.1093/eurheartj/ehz785
Abstract

Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.

Keywords

Hypertriglyceridaemia; Lipoproteins; Review; Treatment; Triglycerides.

Figures
Products